|
IntelligentMDx Completes Major Expansion at Cambridge Research Facility
IntelligentMDx recently completed a significant expansion at its Cambridge location. The project focused on adding space for additional laboratories including expanded BL-2 capabilites. IntelligentMDx’s new state-of-the-art facility occupies 18,000 square feet of 19 Blackstone Street, doubling the size of its existing facility.
“IntelligentMDx is going through a period of demand driven growth and this new location will enable us to better service our customers, now and in the future. We have designed a world class facility with unparalleled features.” said Alice Jacobs, Chairman and CEO of IntelligentMDx.
About IntelligentMDx
IntelligentMDx’s mission is to make FDA approved diagnostic kits. To guarantee quality for customers and partners, we design, develop and manufacture tests under FDA Quality System Regulations and ISO 13485:2003 guidelines. These tests have been, and will be, designed to run on a broad range of molecular systems for clinical diagnostics, drug development and applied sciences.
IntelligentMDx designs, develops and commercializes clinically impactful molecular diagnostic tests. Our goal is to support clinicians in their efforts to provide care with certainty. Our commercial offerings include emerging and re-emerging infectious threats and are available for use in CLIA laboratories covering the rapidly growing markets for transplant and health care-associated infections. IntelligentMDx’s expertise spans evolutionary biology, bioinformatics, and wet lab/molecular biology capabilities, harnessed by our proprietary product development process allowing for the rapid design and development of tests to meet clinical needs.
Media Contact:
For more information on IntelligentMDx, visit www.IntelligentMDx.com or contact Corporate Communications at cc@IntelligentMDx.com, 617-871-6400.
|